Evidence map›Paper›PMID 39802831›Full record

ArticleData in brief2025

Data characterizing a panel of biodegradable cross-linked polyester implants for sustained delivery of an anti-viral drug.

Sungmin Jung, Jack Bufton, Zeqing Bao, Wonjoon Cho, Dean Aguiar, Christine Allen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sungmin JungLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.
Jack BuftonLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.
Zeqing BaoLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.
Wonjoon ChoLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.
Dean AguiarPendant Inc, JLabs Toronto, 661 University Avenue, Suite 1300, Toronto M5G 0B7, Canada.
Christine AllenLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto M5S 3M2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir alafenamide (TAF) is currently administered orally to patients for treatment of chronic hepatitis B virus infection and as a part of a combination therapy for human immunodeficiency virus (HIV) infection. A long-acting delivery system could provide several advantages as a formulation strategy for this drug including improved patient adherence, convenience, more consistent drug levels and potentially fewer side effects. To date, the vast majority of polymer-based long-acting delivery systems have been prepared from poly(lactide-

Indexed as

Long-acting therapeuticsPharmaceuticsPolymersSustained releaseTenofovir alafenamide

Identifiers

PMID39802831
PMCPMC11719335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.